ELZONRIS®
Publications
New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.
Presentations
Outcomes of Tagraxofusp (SL-401) in Older Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). JSH 2019.
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). EHA 2019.
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. EHA 2019.
Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2019.
CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are susceptible to the cytotoxic activity of tagraxofusp, a CD123-targeted therapy. EULAR 2019.
Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). ASCO 2019.
SL-801
Nothing found.
SL-701
Nothing found.